# F182112

Source: https://onco.cc/drugs/f182112/  
OnCo record `f182112` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

F182112 is an experimental investigational agent whose form is not stated in the registry from Shandong New Time Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.

## Summary

F182112 is an investigational agent whose form is not stated in the registry developed by Shandong New Time Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07579234 (A Multicenter, Randomised, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma), in multiple myeloma. The largest, NCT07579234, plans to enrol 261 participants with primary completion expected 2029-01-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: F182112 single-agent
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of F182112: https://clinicaltrials.gov/search?intr=F182112

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- trials: [A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07579234/), [A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07312188/)
- companies: [Shandong New Time Pharmaceutical](https://onco.cc/companies/shandong-new-time-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/f182112.json